Revance Therapeutics, Inc. 4
4 · Revance Therapeutics, Inc. · Filed Nov 17, 2015
Insider Transaction Report
Form 4
Bertolino Arthur Peter
EVP and Chief Medical Officer
Transactions
- Sale
Common Stock
2015-11-17$39.11/sh−5,425$212,172→ 36,329 total - Sale
Common Stock
2015-11-17$39.55/sh−15$593→ 34,001 total - Sale
Common Stock
2015-11-17$39.55/sh−36$1,424→ 36,293 total - Sale
Common Stock
2015-11-17$39.11/sh−2,277$89,053→ 34,016 total
Footnotes (2)
- [F1]The Reporting Person sold an aggregate of 5,461 shares of restricted stock to settle a personal tax liability in connection with the November 15, 2015 vesting of certain shares of restricted stock that the Reporting Person acquired pursuant to a grant dated September 2, 2014.
- [F2]The Reporting Person sold an aggregate of 2,292 shares of restricted stock to settle a personal tax liability in connection with the November 15, 2015 vesting of certain shares of restricted stock that the Reporting Person acquired pursuant to a grant dated January 28, 2015.